Trial Profile
Pre-Surgical Androgen Deprivation Therapy With or Without Axitinib in Previously Untreated Prostate Cancer Patients With Known or Suspected Lymph Node Metastasis
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 02 Jun 2023
Price :
$35
*
At a glance
- Drugs Axitinib (Primary) ; Antiandrogens
- Indications Adenocarcinoma; Cancer metastases; Prostate cancer
- Focus Therapeutic Use
- 02 Jun 2023 Planned End Date changed from 30 Jun 2023 to 30 Jun 2024.
- 02 Jun 2023 Planned primary completion date changed from 30 Jun 2023 to 30 Jun 2024.
- 07 Dec 2022 Planned End Date changed from 31 Dec 2022 to 30 Jun 2023.